KFDA to lift restriction of joint bioequivalence testing

Published: 2010-11-12 07:00:00

Updated: 2010-11-12 07:00:00

From November next year, drug makers will be able to make joint (commissioned) bioequivalence testing without any restriction, according to the Korea Food and Drug Administration.

“We decided to follow the suggestions by the National Reform Committee to shorten the grace period from 3 years to...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK